OGT announced the launch of the RNA-based SureSeq Myeloid Fusion Panel, a new next-generation sequencing (NGS) tool for identifying key fusion genes implicated in acute myeloid leukaemia (AML).
Designed in collaboration with myeloid cancer experts, the SureSeq Myeloid Fusion Panel ensures results meet the latest clinical research recommendations by identifying over 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. By utilizing a partner-gene agnostic approach, fusions with multiple partners as well as novel and rare fusions can be identified, expanding the ability to classify samples.
This panel is fully compatible with OGT’s existing end-to-end Universal NGS Complete Workflow Solution, and complimentary data analysis software, Interpret.
